On 13 June the Supreme Court of the United States published their decision to ban patents on natural human genes, doubtless one of the most-awaited rulings this year. Nevertheless, patents will be allowed for the production of synthetic DNA. This ruling will affect Myriad Genetics, a Salt Lake City firm which holds patents to two genes associated to breast and ovarian cancer (Nature.com, 13-07-2013).